← All trials
NCT02579759
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2015
- Primary completion
- Mar 1, 2018
- Completion date
- Mar 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 323
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Pharnext SALead sponsor
- Katholieke Universiteit LeuvenOverall official - principal investigator
- Salford Royal Foundation NHS TrustOverall official - principal investigator
- University of MunsterOverall official - principal investigator
- Aix-University of MarseilleOverall official - principal investigator
- University of AmsterdamOverall official - principal investigator
- St. Louis UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.